PCA
NKTR icon

Pallas Capital Advisors’s Nektar Therapeutics NKTR Stock Holding History

Pallas Capital Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,298
Closed -$23.4K – 905
2025
Q1 		$23.4K Buy
+2,298
New +$30K ﹤0.01% 740

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pallas Capital Advisors's NKTR Position: Q2 2025 in Review

Pallas Capital Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 2,298 shares — an estimated $23.4K sold.

Pallas Capital Advisors first reported a position in NKTR in Q1 2025 and held it in 1 quarter. The position peaked at $23.4K in Q1 2025. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Pallas Capital Advisors reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Pallas Capital Advisors sold 2,298 Nektar Therapeutics shares in Q2 2025, an estimated $23.4K.
  • Pallas Capital Advisors first reported a position in Nektar Therapeutics in Q1 2025 and held it in 1 quarter.
  • Pallas Capital Advisors's Nektar Therapeutics position peaked at $23.4K in Q1 2025.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Pallas Capital Advisors's 13F filing for Q2 2025, filed 9 Jul 2025.